Last year, a 74-year old woman was diagnosed with inoperable pancreatic cancer. Her family turned to Miami Cancer Institute in their search for treatment options. Since her diagnosis, she became part of the TIGeR-PaC clinical trial, and is now in a maintenance phase and says her quality of life has improved.
TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer
September 2, 2026
A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV delivery in locally advanced pancreatic cancer.